# ARMGO Pharma

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/armgo-pharma

- Industry: Biotechnology
- Headquarters: US
- Website: www.armgo.com
- Total disclosed funding: $35M
- Latest round: Series B (Dec 20, 2021)
- Investors on record: 3

## About

Based in the US, ARMGO Pharma, Inc. focuses on advancing innovative therapeutics targeting critical ion channels for muscle contraction, specifically in the treatment of heart failure through their proprietary Rycals® technology.ARMGO Pharma, Inc. specializes in developing therapeutics aimed at ryanodine receptors (RyRs) crucial for calcium flow and muscle function. Founded in 2004, the headquarters is located in the US. Gene Marcantonio serves as the CEO. The company has successfully completed four funding rounds, with the latest being a SERIES B round in which it raised USD 35.00 mn led by Forbion alongside investors Aliment Capital and Kurma Partners, marking the total amount raised to USD 35.00 mn.RyCarma Therapeutics, a division of ARMGO Pharma, develops a novel class of therapeutics known as Rycals®, specifically targeting ryanodine receptors (RyRs) to regulate intracellular calcium flow and muscle contraction. Their lead candidate, Surlorian, addresses heart failure by enhancing cardiac and skeletal muscle cell function. The company focuses on unmet medical needs in serious diseases, primarily serving healthcare providers and patients in North America and Europe, where there is a significant demand for innovative heart failure therapies.RyCarma Therapeutics generates revenue through the development and commercialization of its flagship therapeutic, Surlorian. The company engages in B2B transactions with healthcare providers and research institutions, establishing partnerships for clinical trials and distribution. Revenue will evolve as the company progresses through clinical phases and enters the market, reflecting the pricing structure of Rycals® aligned with industry standards for advanced therapeutics.ARMGO Pharma, Inc. plans to further develop and launch new products within its Rycals® therapeutic line. The company is targeting expansion into new markets in Europe and North America by the end of 2025. The recent funding from MaasInvest will support these initiatives, ensuring sufficient resources are allocated towards product development and market outreach.

## Funding rounds

- Series B, Dec 20, 2021, $35M — Forbion, Kurma Partners, Aliment Capital

## Investors

- Forbion (https://capitalatlas.ai/funds/forbion) — Series B
- Kurma Partners (https://capitalatlas.ai/funds/kurma-partners) — Series B
- Aliment Capital (https://capitalatlas.ai/funds/aliment-capital) — Series B